Movement disorders clinical practice · 2026
Continuous Apomorphine Infusion in Multiple System Atrophy Real-World Insights From a French Nationwide Retrospective Cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lamy Simon, Leh Frederique, Foubert-Samier Alexandra, Leguy Bonnet Soizic, Baille Guillaume, Fabbri Margherita, Dunoyer Margaux, Mantisi Lise, Giordana Caroline, El Ouartassi Anaïs, Rascol Olivier, Meissner Wassilios G, Bendetowicz David, Vanel Marie, Grabli David, Ory-Magne Fabienne, Drapier Sophie
Аннотация
BACKGROUND: Continuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA).
OBJECTIVE: To assess the 6-month efficacy and tolerability of CSAI in MSA patients.
METHODS: French multicenter retrospective registry-based analysis of CSAI use in MSA. The primary outcome was the 6-month clinical response using the Clinical Global Impression Improvement (CGI-I) scale. Secondary outcomes included tolerability, indications, infusion parameters, and treatment course.
RESULTS: Fifty patients were included; 94% had MSA-P. All had motor fluctuations and 88% showed a clinically meaningful dopaminergic response. CSAI was initiated for motor symptoms (100%) or pain (54%). At 6 months, most patients improved (36% "much," 54% "minimally"), mainly due to reduced motor fluctuations. Only 8% discontinued CSAI. Tolerability was rated good/excellent in 74%; 20% reported somnolence and/or orthostatic hypotension.
CONCLUSION: In selected MSA patients with partial dopaminergic responsiveness and motor fluctuations, CSAI provided short-term clinical benefit with acceptable tolerability.
OBJECTIVE: To assess the 6-month efficacy and tolerability of CSAI in MSA patients.
METHODS: French multicenter retrospective registry-based analysis of CSAI use in MSA. The primary outcome was the 6-month clinical response using the Clinical Global Impression Improvement (CGI-I) scale. Secondary outcomes included tolerability, indications, infusion parameters, and treatment course.
RESULTS: Fifty patients were included; 94% had MSA-P. All had motor fluctuations and 88% showed a clinically meaningful dopaminergic response. CSAI was initiated for motor symptoms (100%) or pain (54%). At 6 months, most patients improved (36% "much," 54% "minimally"), mainly due to reduced motor fluctuations. Only 8% discontinued CSAI. Tolerability was rated good/excellent in 74%; 20% reported somnolence and/or orthostatic hypotension.
CONCLUSION: In selected MSA patients with partial dopaminergic responsiveness and motor fluctuations, CSAI provided short-term clinical benefit with acceptable tolerability.